JP2024522988A5 - - Google Patents
Info
- Publication number
- JP2024522988A5 JP2024522988A5 JP2023574133A JP2023574133A JP2024522988A5 JP 2024522988 A5 JP2024522988 A5 JP 2024522988A5 JP 2023574133 A JP2023574133 A JP 2023574133A JP 2023574133 A JP2023574133 A JP 2023574133A JP 2024522988 A5 JP2024522988 A5 JP 2024522988A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dose
- administered
- therapeutically effective
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195401P | 2021-06-01 | 2021-06-01 | |
| US63/195,401 | 2021-06-01 | ||
| US202163279423P | 2021-11-15 | 2021-11-15 | |
| US63/279,423 | 2021-11-15 | ||
| PCT/US2022/031559 WO2022256304A1 (en) | 2021-06-01 | 2022-05-31 | Peptides and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522988A JP2024522988A (ja) | 2024-06-25 |
| JP2024522988A5 true JP2024522988A5 (https=) | 2025-06-09 |
Family
ID=84323526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574133A Pending JP2024522988A (ja) | 2021-06-01 | 2022-05-31 | ペプチドおよび使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240209036A1 (https=) |
| EP (1) | EP4346866A4 (https=) |
| JP (1) | JP2024522988A (https=) |
| KR (1) | KR20240016323A (https=) |
| AU (1) | AU2022286333A1 (https=) |
| BR (1) | BR112023024988A2 (https=) |
| CA (1) | CA3215620A1 (https=) |
| IL (1) | IL308683A (https=) |
| MX (1) | MX2023014326A (https=) |
| WO (1) | WO2022256304A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022094372A1 (en) * | 2020-11-02 | 2022-05-05 | Realta Life Sciences, Inc. | Peptides and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10005818B2 (en) * | 2010-07-21 | 2018-06-26 | Realta Holdings, Llc | Derivative peptide compounds and methods of use |
| JP6698276B2 (ja) * | 2012-01-16 | 2020-05-27 | アトックス バイオ リミテッド | 細菌感染の治療用の合成ペプチド |
| LT3286181T (lt) * | 2015-04-22 | 2021-04-26 | Rigel Pharmaceuticals, Inc. | Pirazolo junginiai ir junginių gamybos bei naudojimo būdas |
| EP3740074B1 (en) * | 2018-01-09 | 2024-11-06 | ReAlta Holdings, LLC | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
-
2022
- 2022-05-31 JP JP2023574133A patent/JP2024522988A/ja active Pending
- 2022-05-31 US US18/288,274 patent/US20240209036A1/en active Pending
- 2022-05-31 WO PCT/US2022/031559 patent/WO2022256304A1/en not_active Ceased
- 2022-05-31 AU AU2022286333A patent/AU2022286333A1/en active Pending
- 2022-05-31 EP EP22816710.2A patent/EP4346866A4/en active Pending
- 2022-05-31 MX MX2023014326A patent/MX2023014326A/es unknown
- 2022-05-31 IL IL308683A patent/IL308683A/en unknown
- 2022-05-31 KR KR1020237044779A patent/KR20240016323A/ko active Pending
- 2022-05-31 BR BR112023024988A patent/BR112023024988A2/pt unknown
- 2022-05-31 CA CA3215620A patent/CA3215620A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018201801B2 (en) | Combination therapy for treatment of multiple sclerosis | |
| Tanasescu et al. | Advances in the treatment of relapsing-remitting multiple sclerosis | |
| IL300151A (en) | Combinations for cancer treatment | |
| CZ187097A3 (cs) | Farmaceutický prostředek | |
| JP2012505883A5 (https=) | ||
| JP2017529382A5 (https=) | ||
| JP2020535149A5 (https=) | ||
| JP2022019973A5 (https=) | ||
| JP2019501886A5 (https=) | ||
| JP7818412B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2022533981A5 (https=) | ||
| JP2020158544A5 (https=) | ||
| JPWO2020250915A5 (https=) | ||
| JP2024522988A5 (https=) | ||
| BG60400B2 (bg) | Синергитични фармацевтични препарати, тяхното получаване и употребата им | |
| Gonsette | Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis | |
| JP2022514561A5 (https=) | ||
| JP2024544500A5 (https=) | ||
| JP2022513029A5 (https=) | ||
| JP2024512558A5 (https=) | ||
| ES2935265T3 (es) | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control | |
| EP3558378A1 (en) | Low dose drug combinations for use in preventing and treating neuronal damage | |
| Deedwania et al. | Trials and tribulations associated with angina and traditional therapeutic approaches | |
| JP2024503379A5 (https=) | ||
| Lassmann | Mechanisms of multiple sclerosis |